Skip Navigation



JAC Advance Access published online on April 19, 2008
Journal of Antimicrobial Chemotherapy, doi:10.1093/jac/dkn172
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow All Versions of this Article:
62/2/422    most recent
dkn172v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Capone, A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Capone, A.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The Author 2008. Published by Oxford University Press on behalf of the British Society for Antimicrobial Chemotherapy. All rights reserved. For Permissions, please e-mail: journals.permissions@oxfordjournals.org

Research letter

In vitro activity of tigecycline against multidrug-resistant Acinetobacter baumannii

Alessandro Capone1,{dagger}, Silvia D’Arezzo1,{dagger}, Paolo Visca1,2,*,{dagger}, Nicola Petrosillo on behalf of the Gruppo Romano Acinetobacter baumannii1,{dagger}

1 National Institute for Infectious Diseases ‘Lazzaro Spallanzani’, Via Portuense 292, 00149 Rome, Italy 2 Department of Biology, University Roma Tre, Viale Marconi 446, 00146 Rome, Italy

* Correspondence address. Molecular Microbiology Unit, National Institute for Infectious Diseases ‘Lazzaro Spallanzani’, Via Portuense 292, 00149 Rome, Italy. Tel: +39-0655176347; Fax: +39-0655176321; E-mail: visca@uniroma3.it

Key Words: antibiotics , GAR-936 , glycylcyclines , tetracyclines

The first 10% of the full text of this article appears below.

Sir,

Acinetobacter baumannii has emerged as a leading nosocomial pathogen, particularly in intensive care units (ICUs), where several outbreaks have been described.1

Treatment of severe A. baumannii infection represents a difficult clinical challenge due to the propensity of this organism to acquire antimicrobial resistance, resulting in the emergence of multi- and pan-resistant clones.1 There are few therapeutic options to combat multidrug-resistant (MDR) A. baumannii.1

Tigecycline, a new semi-synthetic tetracycline, has provided hope for the treatment of bacterial infections.2 Literature data on the in vitro activity . . . [Full Text of this Article]


   Funding
 

   Transparency declarations
 

Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?